# US 2021/0171522 A1 · Derivatives of an fgfr inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171522 A1
- Document ID: US20210171522A1
- Status: Published application
- Kind: A1
- Application number: 17/110,875
- Filed: 2020-12-03
- Published: 2021-06-10
- Earliest claimed: 2019-12-04
- Assignees: Incyte Corporation
- Applicants: Incyte Corporation
- Inventors: Ming Tao; Jason Boer
- Web page: https://patentgrep.com/patent/US20210171522A1

## CPC

- C07D 471/04: Ortho-condensed systems
- C07D 471/14: Ortho-condensed systems
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.

## Claims

### Claim 1

A compound which is selected from:
3-(2,6-difluoro-3-hydroxy-5-methoxyphenyl)-1-ethyl-8-(morpholinomethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one; and
3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-4-hydroxy-8-(morpholinomethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, which is 3-(2,6-difluoro-3-hydroxy-5-methoxyphenyl)-1-ethyl-8-(morpholinomethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one, or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1, which is 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-4-hydroxy-8-(morpholinomethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one, or a pharmaceutically acceptable salt thereof.

### Claim 4

A compound of Formula II:
wherein one C—H group is replaced with a C—X group, the N—H group is replaced with an N—X group, or the O—H group is replaced with an O—X group; wherein X is a group selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein X is

### Claim 6 (depends on 4)

The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein X is

### Claim 7 (depends on 4)

The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein one C—H group is replaced with a C—X group.

### Claim 8 (depends on 4)

The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein the N—H group is replaced with an N—X group.

### Claim 9 (depends on 4)

The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein the O—H group is replaced with an O—X group.

### Claim 10

A compound which is 3-(2,6-difluoro-3,5-bis(methoxy-d3)phenyl)-1-ethyl-8-(morpholinomethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one, or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

The compound of claim 1, or pharmaceutically acceptable salt thereof, which is substantially isolated.

### Claim 12 (depends on 1)

A composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

The composition of claim 12 which is suitable for oral administration.

### Claim 14 (depends on 12)

The composition of claim 12 which is suitable for intravenous administration.

### Claim 15 (depends on 12)

The composition of claim 12 which is suitable for arterial administration.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the arterial administration is hepatic arterial infusion.

### Claim 17 (depends on 1)

A method of inhibiting an FGFR enzyme comprising contacting the enzyme with a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

A method of treating cancer in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the cancer is selected from bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, thyroid cancer, skin cancer. leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, acute myelogenous leukemia, Hodgkin's or non-Hodgkin's lymphoma, Waldenstrom's Macroglubulinemia, hairy cell lymphoma, Burkett's lymphoma, glioblastoma, melanoma, and rhabdosarcoma.

### Claim 20 (depends on 1)

A method of treating a myeloproliferative disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 20)

The method of claim 20, wherein said myeloproliferative disorder is selected from polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

### Claim 22 (depends on 1)

A method of treating a skeletal or chondrocyte disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 22)

The method of claim 22 wherein said skeletal or chondrocyte disorder is selected from achrondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD), Apert syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosynostosis syndrome.

### Claim 24 (depends on 1)

A method of treating a hypophosphatemia disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 24)

The method of claim 24 wherein said hypophosphatemia disorder is X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, autosomal dominant hypophosphatemic rickets, or tumor-induced osteromalacia.

### Claim 26 (depends on 1)

A method of treating cholangiocarcinoma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 26)

The method of claim 26, wherein the cholangiocarcinoma is advanced or metastatic cholangiocarcinoma.

### Claim 28 (depends on 1)

A method of treating myeloid/lymphoid neoplasms in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 29 (depends on 28)

The method of claim 28, wherein the myeloid/lymphoid neoplasm is 8p11 myeloproliferative syndrome.

### Claim 30 (depends on 28)

The method of claim 28, wherein the myeloid/lymphoid neoplasm is associated with eosinophilia.

### Claim 31

A process of preparing Compound 2 having the formula:
or a salt thereof, comprising:
a) reacting Compound F1 having the formula:
with an amino protecting agent, to provide Compound F2 having the formula:
or a salt thereof, wherein P1 is an amino protecting group;
b) reacting Compound F2 with DMF in the presence of B1, wherein B1 is a base, to provide Compound F3 having the formula:
or a salt thereof,
c) reacting Compound F3 with morpholine in the presence of RA1, wherein RA1 is a reducing agent, to provide Compound F4 having the formula:
or a salt thereof, and
d) deprotecting Compound F4 to provide Compound 2, or a salt thereof.

### Claim 32

A process for preparing Compound 6 having the formula:
or a salt thereof, comprising:
a) reacting Compound F7 having the formula:
with A3, wherein A3 is a Lewis acid, and wherein P2 is an amino protecting group, to provide Compound F6 having the formula:
or a salt thereof,
b) reacting Compound F6 with CD3I in the presence of B4, wherein B4 is a base, to provide Compound F5 having the formula:
or a salt thereof, and
c) deprotecting Compound F5 to provide Compound 6, or a salt thereof.

### Claim 33

A compound selected from:
or a salt of any of the aforementioned.

### Claim 34

A compound selected from:
or a salt of any of the aforementioned.
